Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence
Authors
Keywords
-
Journal
EPIDEMIOLOGY AND INFECTION
Volume 145, Issue 10, Pages 1962-1982
Publisher
Cambridge University Press (CUP)
Online
2017-04-27
DOI
10.1017/s0950268817000747
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria
- (2016) L. Boiron et al. BMC INFECTIOUS DISEASES
- Public health value of universal HPV vaccination
- (2016) Riccardo A. Audisio et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Ten years of HPV vaccines: State of art and controversies
- (2016) Roberto Angioli et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Age-specific prevalence of HPV16/18 genotypes in cervical cancer: A systematic review and meta-analysis
- (2016) Anne Hammer et al. INTERNATIONAL JOURNAL OF CANCER
- Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine
- (2016) Harrell W. Chesson et al. JOURNAL OF INFECTIOUS DISEASES
- Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines
- (2016) Pierre Van Damme et al. VACCINE
- A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men
- (2016) Pierre Van Damme et al. VACCINE
- An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany
- (2016) Nathalie Largeron et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Human Papillomavirus–Associated Cancers — United States, 2008–2012
- (2016) Laura J. Viens et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France
- (2015) Didier Riethmuller et al. BMC PUBLIC HEALTH
- Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine
- (2015) Alain Luxembourg et al. Contemporary Clinical Trials
- Prophylactic HPV vaccination: past, present, and future
- (2015) P. E. CASTLE et al. EPIDEMIOLOGY AND INFECTION
- Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions
- (2015) Beatriz Serrano et al. EUROPEAN JOURNAL OF CANCER
- Seroprevalence of 9 Human Papillomavirus Types in the United States, 2005–2006
- (2015) Gui Liu et al. JOURNAL OF INFECTIOUS DISEASES
- A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women
- (2015) Elmar A. Joura et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Open-Label, Randomized Study of a 9-Valent Human Papillomavirus Vaccine Given Concomitantly with Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccines to Healthy Adolescents 11–15 Years of Age
- (2015) Pope Kosalaraksa et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9–15-Year-Old Girls
- (2015) Timo Vesikari et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Coadministration of a 9-Valent Human Papillomavirus Vaccine With Meningococcal and Tdap Vaccines
- (2015) A. Schilling et al. PEDIATRICS
- Immunogenicity and Safety of a 9-Valent HPV Vaccine
- (2015) P. Van Damme et al. PEDIATRICS
- Safety and immunogenicity of a 9-valent HPV vaccine in females 12–26 years of age who previously received the quadrivalent HPV vaccine
- (2015) Suzanne M. Garland et al. VACCINE
- Immunogenicity and safety of the 9-valent HPV vaccine in men
- (2015) X. Castellsagué et al. VACCINE
- Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine
- (2015) Alain Luxembourg et al. Human Vaccines & Immunotherapeutics
- Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine
- (2015) Alain Luxembourg et al. Human Vaccines & Immunotherapeutics
- Potential impact of a 9-valent HPV vaccine in HPV-related cervical disease in 4 emerging countries (Brazil, Mexico, India and China)
- (2014) Beatriz Serrano et al. Cancer Epidemiology
- HPV Type Attribution in High-Grade Cervical Lesions: Assessing the Potential Benefits of Vaccines in a Population-Based Evaluation in the United States
- (2014) S. Hariri et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Human Papillomavirus Genotype-Specific Prevalence across the Continuum of Cervical Neoplasia and Cancer
- (2014) N. E. Joste et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease
- (2014) E. A. Joura et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Costs and Cost-Effectiveness of 9-Valent Human Papillomavirus (HPV) Vaccination in Two East African Countries
- (2014) Sorapop Kiatpongsan et al. PLoS One
- Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine
- (2014) Paulo S Naud et al. Human Vaccines & Immunotherapeutics
- Towards the eradication of HPV infection through universal specific vaccination
- (2013) Piergiorgio Crosignani et al. BMC PUBLIC HEALTH
- Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine
- (2013) Mélanie Drolet et al. INTERNATIONAL JOURNAL OF CANCER
- Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer
- (2012) Peng Guan et al. INTERNATIONAL JOURNAL OF CANCER
- A population-based study of human papillomavirus genotype prevalence in the United States: Baseline measures prior to mass human papillomavirus vaccination
- (2012) Cosette M. Wheeler et al. INTERNATIONAL JOURNAL OF CANCER
- Population-Level Impact of the Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines: A Model–Based Analysis
- (2012) Nicolas Van de Velde et al. JNCI-Journal of the National Cancer Institute
- Global burden of cancers attributable to infections in 2008: a review and synthetic analysis
- (2012) Catherine de Martel et al. LANCET ONCOLOGY
- Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease
- (2012) Beatriz Serrano et al. Infectious Agents and Cancer
- HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women
- (2010) Maura L. Gillison et al. CANCER
- Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication
- (2010) Ni Li et al. INTERNATIONAL JOURNAL OF CANCER
- Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
- (2010) Silvia de Sanjose et al. LANCET ONCOLOGY
- Human Papillomavirus (HPV) Vaccines: Limited Cross‐Protection against Additional HPV Types
- (2009) Rolando Herrero JOURNAL OF INFECTIOUS DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now